FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 13:08:38 2024-05-27 EDT | ||
| 76.19 EUR | -0.95% |
|
| Current month | +71.28% | ||
| 1 month | +58.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 76.19 | -0.95% |
| 24-05-24 | 76.92 | +4.62% |
| 24-05-23 | 73.52 | +3.45% |
| 24-05-22 | 71.07 | +5.43% |
| 24-05-21 | 67.41 | -5.08% |
Delayed Quote Deutsche Boerse AG
Last update May 27, 2024 at 01:08 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF6JA4 |
| ISIN | DE000SF6JA41 |
| Date issued | 2021-11-11 |
| Strike | 191.1 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 82.26 € |
|---|---|
| Lowest since issue | 8.58 € |
| Spread | 3.12 € |
| Spread % | 3.86% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
